Traditional Chinese Medicine Compound Treats Rosacea by Reducing LL-37 and Macrophage Inflammation

Paeoniflorin inhibited LL-37 (cathelicidin) expression and macrophage-mediated rosacea inflammation through the SOCS3-ASK1-p38 pathway, reducing the abnormal immune response that drives this chronic skin condition.

Liu, Zijing et al.·Medicine·2021·Preliminary Evidencein vitro
RPEP-05566In vitroPreliminary Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in vitro
Evidence
Preliminary Evidence
Sample
N=N/A (cell culture + tissue samples)
Participants
RAW 264.7 macrophage cells; human granulomatous rosacea tissue samples

What This Study Found

Paeoniflorin promoted SOCS3 expression and inhibited LPS-induced TLR2 and LL-37 expression through SOCS3-ASK1-p38 cascade in macrophages. Rosacea lesions showed increased LL-37 and CD68+ macrophage infiltration. SOCS3 siRNA reversed PF's effects, confirming the mechanism.

Key Numbers

Pathway: SOCS3-ASK1-p38; reduced TLR2 and LL37; CD68+ macrophage infiltration in lesions; siRNA confirmation

How They Did This

Clinical tissue analysis + in vitro mechanistic study. Immunohistochemistry of granulomatous rosacea lesions vs peripheral tissue. RAW 264.7 macrophage cell model with LPS stimulation. PF treatment effects on SOCS3, ASK1-p38, TLR2, and LL-37. SOCS3 siRNA knockdown for mechanism confirmation.

Why This Research Matters

LL-37 overexpression is a recognized driver of rosacea inflammation, but current treatments don't specifically target this pathway. PF offers a mechanism-based approach to treating the root cause of rosacea rather than just managing symptoms.

The Bigger Picture

LL-37/cathelicidin drives multiple inflammatory skin conditions including rosacea, psoriasis, and acne. Finding compounds that specifically reduce LL-37 overexpression could benefit millions of people with these conditions.

What This Study Doesn't Tell Us

In vitro macrophage model with LPS stimulation — rosacea triggers are more complex. No in vivo rosacea model tested. PF bioavailability for topical skin application unknown. Clinical trial data needed.

Questions This Raises

  • ?Would topical paeoniflorin formulations effectively treat rosacea in patients?
  • ?Does PF reduce LL-37 in other inflammatory skin conditions like psoriasis?
  • ?Could PF be combined with standard rosacea treatments for enhanced benefit?

Trust & Context

Key Stat:
Targets LL-37 overexpression Paeoniflorin specifically reduces the LL-37 cathelicidin peptide overexpression that drives rosacea inflammation — addressing the root cause, not just symptoms
Evidence Grade:
Low-to-moderate evidence: combined clinical tissue analysis and mechanistic in vitro study with siRNA confirmation, but no clinical treatment trial.
Study Age:
Published 2021. LL-37-targeted therapies for inflammatory skin diseases are an active research area.
Original Title:
Paeoniflorin inhibits the macrophage-related rosacea-like inflammatory reaction through the suppressor of cytokine signaling 3-apoptosis signal-regulating kinase 1-p38 pathway.
Published In:
Medicine, 100(3), e23986 (2021)
Database ID:
RPEP-05566

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What causes rosacea at the molecular level?

Rosacea involves overexpression of LL-37, an antimicrobial peptide that triggers inflammation when present at excessive levels. Combined with abnormal macrophage infiltration, this creates the chronic facial redness, bumps, and flushing that characterize rosacea.

Could peony root help with rosacea?

This study shows paeoniflorin (from peony root) suppresses the LL-37 overexpression and macrophage inflammation that drive rosacea. While promising, this is lab evidence — clinical trials would be needed to confirm benefits for rosacea patients.

Read More on RethinkPeptides

Cite This Study

RPEP-05566·https://rethinkpeptides.com/research/RPEP-05566

APA

Liu, Zijing; Zhang, Jiawen; Jiang, Peiyu; Yin, Zhi; Liu, Yunyi; Liu, Yixuan; Wang, Xiaoyan; Hu, Liang; Xu, Yang; Liu, Wentao. (2021). Paeoniflorin inhibits the macrophage-related rosacea-like inflammatory reaction through the suppressor of cytokine signaling 3-apoptosis signal-regulating kinase 1-p38 pathway.. Medicine, 100(3), e23986. https://doi.org/10.1097/MD.0000000000023986

MLA

Liu, Zijing, et al. "Paeoniflorin inhibits the macrophage-related rosacea-like inflammatory reaction through the suppressor of cytokine signaling 3-apoptosis signal-regulating kinase 1-p38 pathway.." Medicine, 2021. https://doi.org/10.1097/MD.0000000000023986

RethinkPeptides

RethinkPeptides Research Database. "Paeoniflorin inhibits the macrophage-related rosacea-like in..." RPEP-05566. Retrieved from https://rethinkpeptides.com/research/liu-2021-paeoniflorin-inhibits-the-macrophagerelated

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.